- Home
- MLAC vs DRUG Comparison
MLAC vs DRUG Comparison
Compare MLAC & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLAC
- DRUG
- Stock Information
- Founded
- MLAC 2024
- DRUG 2019
- Country
- MLAC United States
- DRUG United States
- Employees
- MLAC N/A
- DRUG N/A
- Industry
- MLAC
- DRUG Pharmaceuticals and Biotechnology
- Sector
- MLAC
- DRUG Health Care
- Exchange
- MLAC NYSE
- DRUG Nasdaq
- Market Cap
- MLAC N/A
- DRUG 233.2M
- IPO Year
- MLAC 2024
- DRUG N/A
- Fundamental
- Price
- MLAC $10.10
- DRUG $32.62
- Analyst Decision
- MLAC
- DRUG Strong Buy
- Analyst Count
- MLAC 0
- DRUG 4
- Target Price
- MLAC N/A
- DRUG $84.33
- AVG Volume (30 Days)
- MLAC 87.2K
- DRUG 30.8K
- Earning Date
- MLAC 01-01-0001
- DRUG 05-16-2025
- Dividend Yield
- MLAC N/A
- DRUG N/A
- EPS Growth
- MLAC N/A
- DRUG N/A
- EPS
- MLAC N/A
- DRUG N/A
- Revenue
- MLAC N/A
- DRUG N/A
- Revenue This Year
- MLAC N/A
- DRUG N/A
- Revenue Next Year
- MLAC N/A
- DRUG N/A
- P/E Ratio
- MLAC $412.08
- DRUG N/A
- Revenue Growth
- MLAC N/A
- DRUG N/A
- 52 Week Low
- MLAC $9.94
- DRUG $0.93
- 52 Week High
- MLAC $10.17
- DRUG $79.02
- Technical
- Relative Strength Index (RSI)
- MLAC N/A
- DRUG 49.10
- Support Level
- MLAC N/A
- DRUG $31.10
- Resistance Level
- MLAC N/A
- DRUG $35.94
- Average True Range (ATR)
- MLAC 0.00
- DRUG 2.46
- MACD
- MLAC 0.00
- DRUG 0.38
- Stochastic Oscillator
- MLAC 0.00
- DRUG 66.76
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.